Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V97.1.256PMID 11133769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased levels of circulating interleukin‐6 in patients with hodgkin's disease

  2006influential reference
• Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.

  2000cited by this paper
• Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

  1999cited by this paper
• High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma.

  1998cited by this paper
• Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells.

  1998cited by this paper
• Diagnosis of human papillomavirus genital tract infection.

  1997cited by this paper
• Interleukin-10 in non-Hodgkin's lymphoma.

  1997cited by this paper
• Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.

  1997cited by this paper
• Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma

  1997cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996influential reference
• Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.

  1996cited by this paper
• Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia.

  1996influential reference
• The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death.

  1995influential reference
• Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas.

  1995cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.

  1995cited by this paper
• Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.

  1995influential reference
• Interleukin-6: a candidate mediator of human prostate cancer morbidity.

  1995cited by this paper
• Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells

  1994cited by this paper
• Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.

  1993cited by this paper
• Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta.

  1993influential reference
• Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.

  1993cited by this paper
• Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma

  1993influential reference
• Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.

  1993cited by this paper
• Cytokine (interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6)-possessing cells in lymph nodes of malignant lymphoma.

  1993cited by this paper
• Interleukin-6 production in posttransplant lymphoproliferative disease.

  1993cited by this paper
• The international standard for interleukin-6. Evaluation in an international collaborative study.

  1993influential reference
• Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

  1992cited by this paper
• Proliferation of the BCL1 B cell lymphoma induced by IL‐4 and IL‐5 is dependent on IL‐6 and GM‐CSF

  1992influential reference
• Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

  1992cited by this paper
• [Immunohistochemical in situ demonstration of cytokines in Hodgkin and non-Hodgkin lymphoma].

  1992cited by this paper
• Ly‐1 B (B‐1) cells are the main source of B cell‐derived interleukin 10

  1992cited by this paper
• Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

  1992cited by this paper
• Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.

  1992influential reference
• Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients.

  1992cited by this paper
• Production of interleukin-6 in high grade B lymphomas.

  1992influential reference
• Long-Term Consequences of Interleukin-6 Overexpression in Transgenic Mice

  1992cited by this paper
• Interleukin-6 levels in the plasma of patients with lymphoma.

  1992cited by this paper
• Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas.

  1992cited by this paper
• Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia.

  1992influential reference
• Interleukin 10: a novel stimulatory factor for mast cells and their progenitors

  1991influential reference
• Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer.

  1991influential reference
• Interleukin-6 is a prognostic factor in multiple myeloma.

  1991influential reference
• Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]

  1991cited by this paper
• Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

  1991cited by this paper
• Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells

  1990influential reference
• Interleukin-6: an overview.

  1990cited by this paper
• Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity

  1990cited by this paper
• Interleukin-6 and the acute phase response.

  1990cited by this paper
• Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer.

  1990cited by this paper
• Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.

  1990cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Interleukin 6 gene expression in normal and neoplastic B cells.

  1989cited by this paper
• Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

  1989influential reference
• A possible autocrine role for interleukin-6 in two lymphoma cell lines.

  1989cited by this paper
• The biology of interleukin-6.

  1989cited by this paper
• Interleukin-6 (B-cell stimulatory factor 2)-dependent growth of a Lennert's lymphoma-derived T-cell line (KT-3).

  1988cited by this paper
• Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.

  1986cited by this paper
• Statistical Methods

  1959cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958influential reference

• Functional differences between CLL‐ and ALL‐derived CAR T cells in a 3D tumor microenvironment highlight CXCR4 and IL‐10 as potential modulatory targets

  2025cites this paper
• Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

  2025cites this paper
• Changes in Serum Inflammatory Markers and in Clinical Periodontal Condition After Non-Surgical Periodontal Treatment in Hypertensive Patients

  2025cites this paper
• Evaluation of interleukin-6 level in patients with chronic lymphocytic leukemia and its correlation with the stage of the disease

  2025cites this paper
• Aptamer‐Mediated Artificial Synapses for Neuromorphic Modulation of Inflammatory Signaling via Organic Electrochemical Transistor

  2025cites this paper
• Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL

  2025cites this paper
• The Impact of Targeted Therapies on Red Blood Cell Aggregation in Patients with Chronic Lymphocytic Leukemia Evaluated Using Software Image Flow Analysis

  2025cites this paper
• Frankincense oil as a novel modulator of epileptic-associated neuroinflammation induced by penicillin in rats

  2025cites this paper
• A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients

  2025cites this paper
• Identification of biomarkers for chronic lymphocytic leukemia risk: a proteome-wide Mendelian randomization study

  2025cites this paper
• Disruption of Marrow Microenvironments in Chronic Lymphocytic Leukemia by High-Resolution Synchrotron Micro-Computed Tomography

  2025cites this paper
• Quantitative Assessment of Red Blood Cell Disaggregation in Chronic Lymphocytic Leukemia via Software Image Flow Analysis

  2025cites this paper
• Interleukin-6 And Interleukin-10 Polymorphisms In Chronic Lymphoid Leukemia Patients

  2024cites this paper
• Bone marrow inflammation in haematological malignancies

  2024cites this paper
• An overview of prognostic markers in patients with CLL

  2024cites this paper
• Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact

  2024cites this paper
• Interleukin-6 and tumor necrosis factor-α levels in chronic lymphocytic leukemia: correlation with patients’ characteristics and outcome

  2024cites this paper
• Relationship between Carotid Intima-Media Thickness, Periodontal Disease, and Systemic Inflammation Biomarkers in an Adult Population

  2024cites this paper
• Potential New Therapies “ROS-Based” in CLL: An Innovative Paradigm in the Induction of Tumor Cell Apoptosis

  2024cites this paper
• Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications

  2024cites this paper
• The Effect of Mind-Body Intervention on Lymphocyte Doubling Time and Treatment-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients

  2024cites this paper
• Assessment and prognostic significance of a serum cytokine panel in diffuse large B‑cell lymphoma

  2024cites this paper
• Inflammation as a driver of hematological malignancies

  2024cites this paper
• Noncontact 3D Bioprinting of Proteinaceous Microarrays for Highly Sensitive Immunofluorescence Detection within Clinical Samples.

  2024cites this paper
• Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia

  2023cites this paper
• Mesenchymal stromal cell senescence in haematological malignancies

  2023cites this paper
• Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia

  2023cites this paper
• Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature

  2023cites this paper
• Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients

  2023cites this paper
• Phagocyte-related S100 proteins and cytokines in acute lymphoblastic leukemia and their prognostic value

  2023cites this paper
• Evaluation the -174G>C Genetic Polymorphism of Interleukin-6 in Iranian Patients with Chronic Lymphocytic Leukemia

  2023cites this paper
• Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers

  2023cites this paper
• Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.

  2022cites this paper
• Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners.

  2022cites this paper
• Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia

  2022cites this paper
• The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?

  2022cites this paper
• High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma

  2022cites this paper
• Evaluation of Interleukin 10 Levels among Pulmonary Tuberculosis Patients Attending Aminu Kano Teaching Hospital, Kano

  2022cites this paper
• Regulation of S100As Expression by Inflammatory Cytokines in Chronic Lymphocytic Leukemia

  2022cites this paper
• Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

  2021cites this paper
• C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases

  2021cites this paper
• Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia

  2021cites this paper
• Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

  2021cites this paper
• Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia

  2021cites this paper
• CLL-like monoclonal B cell lymphocytosis displays an increased inflammatory signature that is reduced in early stage chronic lymphocytic leukemia.

  2021cites this paper
• Reasons and consequences of COVID‐19 vaccine failure in patients with chronic lymphocytic leukemia

  2021cites this paper
• Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells

  2021cites this paper
• Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity.

  2021cites this paper
• P38 MAPK/AKT signalling is involved in IL-33-mediated anti-apoptosis in childhood acute lymphoblastic leukaemia blast cells

  2021cites this paper
• IL10 as Cancer Biomarker

  2020cites this paper
• Macrophage Polarization in Chronic Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells

  2020cites this paper
• Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis

  2020cites this paper
• Levels of Interleukin-10 in Iraqi Childhood Acute Lymphoblastic Leukemia after Chemotherapy

  2020cites this paper
• Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia

  2020cites this paper
• Predictive value of serological factors, maximal standardized uptake value and ratio of Ki67 in patients diagnosed with non-Hodgkin's lymphoma

  2020cites this paper
• Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role

  2020cites this paper
• Antibody Micropatterned Lubricant-Infused Biosensors Enable Sub-Picogram Immunofluorescence Detection of Interleukin 6 in Human Whole Plasma.

  2020cites this paper
• Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy

  2019cites this paper
• Increased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia

  2019cites this paper
• Promoter Polymorphism in the Interleukin-10 Confers an Increased Risk of DLBCL in Chinese

  2019cites this paper
• High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy

  2019cites this paper
• Impedimetric aptasensor for the label-free and selective detection of Interleukin-6 for colorectal cancer screening.

  2019cites this paper
• Diabetes Mellitus Is Associated with Inferior Prognosis in Patients with Chronic Lymphocytic Leukemia: A Propensity Score-Matched Analysis

  2019cites this paper
• In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment

  2019cites this paper
• INFECTION MIMETIC TUMOR FEVER IN ALBANIAN ADULTS: EPIDEMIOLOGICAL AND NOSOGRAPHICAL DATA

  2018cites this paper
• Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy.

  2018cites this paper
• Unravelling the role of the microenvironment in chronic lymphocytic leukaemia: T helper cell support of cancer cells

  2018cites this paper
• BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

  2018cites this paper
• Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma

  2018cites this paper
• Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia

  2018cites this paper
• A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia

  2018cites this paper
• Low T3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia

  2018influential citation
• The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide

  2018cites this paper
• The bone marrow microenvironment in health and disease at a glance

  2018cites this paper
• Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.

  2018cites this paper
• Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

  2018cites this paper
• Expression of Cytokine of Chronic Lymphocyte Leukemia from Baghdad / Iraq Population

  2018cites this paper
• Ultrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements

  2017cites this paper
• Association of Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms with B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians

  2017cites this paper
• Epigenetic Regulation of Interleukin 6 by Histone Acetylation in Macrophages and Its Role in Paraquat-Induced Pulmonary Fibrosis

  2017cites this paper
• Cytokines and soluble HLA‐G levels in bone marrow stroma and their association with the survival rate of patients exhibiting childhood T‐cell acute lymphoblastic leukemia

  2017cites this paper
• Interleukin-6 Level among Iraqi Patients with Chronic Lymphocytic Leukemia from Babil Province

  2017cites this paper
• The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia

  2017cites this paper
• How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.

  2017cites this paper
• IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus

  2017cites this paper
• Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion by Human Regulatory B Cells

  2017cites this paper
• Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia

  2017cites this paper
• Association of IL-2330 T / G and IL-10-1082 A / G genetic polymorphisms with B-NHL in a cohort of Egyptians

  2017cites this paper
• Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.

  2017cites this paper
• Interleukin-24 Concentrations Not Related with Age, but Affect Pro- and Anti-Inflammatory Cytokines Differently in Healthy Donors.

  2017cites this paper
• Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

  2017cites this paper
• An Unusual Triad of Hemophagocytic Syndrome, Lymphoma and Tuberculosis in a Non-HIV Patient

  2017cites this paper
• Cuantificación de citoquinas y su relación con la presencia de bacteriemia en leucemias agudas y neutropenia febril postquimioterapia

  2017cites this paper
• Population B régulatrice dans la leucémie lymphoïde chronique : phénotype et interactions fonctionnelles avec les lymphocytes T en lien avec l’évolutivité

  2017cites this paper
• Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

  2016cites this paper
• Modelling chronic lymphocytic leukaemia (CLL) cell : microenvironment interactions in two- and three-dimensional culture systems

  2016cites this paper
• CD 126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia

  2016cites this paper
• Characterisation of the immuno-inflammatory response following operative adolescent idiopathic scoliosis and biological properties of osteoprogenitor cells harvested from vertebral bodies compared to iliac crest

  2016cites this paper
• SUPPRESSION OF ANTI-TUMOR IMMUNITY IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA INTERLEUKIN-10 PRODUCTION

  2016influential citation
• Improving Therapy of Chronic Lymphocytic Leukemia (CLL) with Chimeric Antigen Receptor (CAR) T Cells

  2016cites this paper